ATE374196T1 - Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen - Google Patents

Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen

Info

Publication number
ATE374196T1
ATE374196T1 AT03702549T AT03702549T ATE374196T1 AT E374196 T1 ATE374196 T1 AT E374196T1 AT 03702549 T AT03702549 T AT 03702549T AT 03702549 T AT03702549 T AT 03702549T AT E374196 T1 ATE374196 T1 AT E374196T1
Authority
AT
Austria
Prior art keywords
dihydrobenzodiazepine
derivatives
treatment
neurological diseases
neurological
Prior art date
Application number
AT03702549T
Other languages
English (en)
Inventor
Geo Adam
Erwin Goetschi
Juergen Wichmann
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE374196T1 publication Critical patent/ATE374196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03702549T 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen ATE374196T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06

Publications (1)

Publication Number Publication Date
ATE374196T1 true ATE374196T1 (de) 2007-10-15

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702549T ATE374196T1 (de) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen

Country Status (30)

Country Link
US (1) US6949542B2 (de)
EP (1) EP1474416B1 (de)
JP (1) JP4077411B2 (de)
KR (1) KR20040081486A (de)
CN (1) CN100497333C (de)
AR (1) AR038481A1 (de)
AT (1) ATE374196T1 (de)
AU (1) AU2003205695B8 (de)
BR (1) BR0307474A (de)
CA (1) CA2474219C (de)
DE (1) DE60316538T2 (de)
DK (1) DK1474416T3 (de)
ES (1) ES2294264T3 (de)
GT (1) GT200300028A (de)
HR (1) HRP20040678A2 (de)
IL (1) IL163102A (de)
MX (1) MXPA04007516A (de)
MY (1) MY176608A (de)
NO (1) NO327697B1 (de)
NZ (1) NZ534122A (de)
PA (1) PA8565901A1 (de)
PE (1) PE20031011A1 (de)
PL (1) PL372425A1 (de)
PT (1) PT1474416E (de)
RU (1) RU2315764C2 (de)
SI (1) SI1474416T1 (de)
TW (1) TWI326599B (de)
UY (1) UY27654A1 (de)
WO (1) WO2003066623A1 (de)
ZA (1) ZA200406032B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779874B2 (en) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives
PL1651234T3 (pl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
ATE463495T1 (de) * 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
MX2009010729A (es) * 2007-04-19 2009-10-26 Hoffmann La Roche Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.
JP5204232B2 (ja) 2007-08-27 2013-06-05 エフ.ホフマン−ラ ロシュ アーゲー Fxrアゴニストとして使用されるベンゾイミダゾール誘導体
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
WO2011021676A1 (ja) 2009-08-21 2011-02-24 大塚製薬株式会社 ベンゾ[b][1,4]ジアゼピン-2,4-ジオン化合物の製造方法
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2661435B1 (de) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2877444B1 (de) 2012-07-27 2020-09-02 The Broad Institute, Inc. Histondeacetylase-hemmer
HK1206615A1 (en) 2012-10-23 2016-01-15 霍夫曼-拉罗奇有限公司 Mglu2/3 antagonists for the treatment of autistic disorders
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
MX2016013711A (es) 2014-04-23 2017-01-13 Hoffmann La Roche Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ[1,5−d][1,4]オキサゼピン化合物(TETRAHYDROIMIDAZO[1,5−d][1,4]OXAZEPINECOMPOUND)
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105839T1 (de) * 1989-03-23 1994-06-15 Pfizer Antiallergische mittel auf der basis von diazepin.
TR200201023T2 (tr) 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
AU779874B2 (en) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives

Also Published As

Publication number Publication date
SI1474416T1 (sl) 2008-02-29
HK1078858A1 (zh) 2006-03-24
AU2003205695B2 (en) 2008-04-03
CN100497333C (zh) 2009-06-10
EP1474416B1 (de) 2007-09-26
KR20040081486A (ko) 2004-09-21
AU2003205695A1 (en) 2003-09-02
WO2003066623A1 (en) 2003-08-14
NO327697B1 (no) 2009-09-14
MY176608A (en) 2020-08-18
AR038481A1 (es) 2005-01-19
HRP20040678A2 (en) 2005-10-31
TW200302730A (en) 2003-08-16
BR0307474A (pt) 2004-11-09
AU2003205695B8 (en) 2008-05-01
CA2474219C (en) 2010-04-13
MXPA04007516A (es) 2004-11-10
PL372425A1 (en) 2005-07-25
ZA200406032B (en) 2005-10-12
NZ534122A (en) 2006-12-22
RU2004126945A (ru) 2005-06-27
ES2294264T3 (es) 2008-04-01
PT1474416E (pt) 2007-12-27
NO20043237L (no) 2004-08-02
TWI326599B (en) 2010-07-01
PE20031011A1 (es) 2003-11-29
IL163102A (en) 2011-07-31
RU2315764C2 (ru) 2008-01-27
UY27654A1 (es) 2003-08-29
JP2005522440A (ja) 2005-07-28
DE60316538T2 (de) 2008-08-21
US6949542B2 (en) 2005-09-27
DK1474416T3 (da) 2008-01-14
US20030166639A1 (en) 2003-09-04
PA8565901A1 (es) 2003-09-05
DE60316538D1 (de) 2007-11-08
CA2474219A1 (en) 2003-08-14
GT200300028A (es) 2004-06-11
CN1633430A (zh) 2005-06-29
EP1474416A1 (de) 2004-11-10
JP4077411B2 (ja) 2008-04-16

Similar Documents

Publication Publication Date Title
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE372674T1 (de) N-arylhydrazonderivate für die saatgutbehandlung
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
ATE333872T1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE355283T1 (de) Isochroman verbindungen für die behandlung von cns-krankheiten
ATE272619T1 (de) Anilin-disulfid-derivate zur behandlung allergischer erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1474416

Country of ref document: EP